The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 1, 1999, Pages 100-106

  Sussman, Gordon L ^a   Mason, Jolene ^b   Compton, Diana ^b   Stewart, John ^c   Ricard, Nancy ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b SANOFI   (France)

^c Hoechst Marion Roussel Canada R   (Canada)

Author keywords

Activity impairment; Antihistamine; Combination therapy; Efficacy; Fexofenadine hydrochloride; Health economics; Pseudoephedrine hydrochloride; Seasonal allergic rhinitis; Work productivity

Indexed keywords

FEXOFENADINE; PSEUDOEPHEDRINE;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; PARALLEL DESIGN; POLLEN ALLERGY; PRIORITY JOURNAL; PRODUCTIVITY; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME;

EID: 0032867084     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70120-X     Document Type: Article

References (28)

1. 1. Tarnasky PR, Van Arsdel PP. Antihistamine therapy in allergic rhinitis. J Fam Pract 1990;30:71-80.
2. 2. Ricketti AJ. Allergic rhinitis. In: Patterson R, editor. Allergic diseases -diagnosis and management. 3rd ed. Philadelphia: JB Lippincott; 1985. p. 207.
3. 3. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83.
4. 4. Storms W, Meltzer EO, Nathan R, Selner J. The economic impact of allergic rhinitis. J Allergy Clin Immunol 1997;99:5820-4.
5. 5. Druce HM, Kaliner MA. Allergic rhinitis. JAMA 1988;259:260-3.
6. 6. Melzer EO. Antihistamine and decongestant-induced performance decrements. J Occup Med 1990;32:327-34.
7. 1-receptor antagonists. An EAACI position paper. Allergy 1996;51:666-75.
8. 8. Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998;55:269-76.
9. 9. Garteiz DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim-Forsch Drug Res 1982;32:1185-90.
10. 10. Lippert C, Ling J, Brown PL, et al. Mass balance and pharmacokinetics of fexofenadine HCl in healthy, male volunteers [abstract]. Pharm Res 1995;12(Suppl 9):S390.
11. 11. Allegra™ (fexofenadine hydrochloride) Capsules 60 mg product insert. Kansas City (MO): Hoechst Marion Roussel, Inc; 1996.
12. 1 receptor antagonists: clinical pharmacology and therapeutics. J Allergy Clin Immunol 1989;84:845-66.
13. 13. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8.
14. 14. Howarth PH, Holgate ST. Comparative trial of two non-sedative HI-antihistamines, terfenadine and astemizole, for hayfever. Thorax 1984;39:668-72.
15. 15. Kemp JP, Buckley CE, Gershwin ME, et al. Multi-centre, double-blind, placebo controlled trial of terfenadine in seasonal allergic rhinitis and conjunctivitis. Ann Allergy 1985;54:502-9.
16. 16. Clissold SP, Sorkin EM, Goa KL. Loratadine: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1989;37:42-57.
17. 17. Pseudoephedrine. In: Reynolds JEF, editor. Martindale: the extra pharmacopoeia. London: Royal Pharmaceutical Society; 1996. p. 1588.
18. 18. Storms WW, Bodman SF, Nathan RA, et al. SCH 434: a new antihistamine/decongestant for seasonal allergic rhinitis. J Allergy Clin Immunol 1989;83:1083-90.
19. 19. Grant JA, Fox R, Hampel F, Harris J, Gross G. Meta-analysis of Hismanal-D clinical trials in seasonal allergic rhinitis (SAR) [abstract]. Allergy 1992;47(Suppl 12):242.
20. 20. Dockhorn RJ, Shellenberger MK, Moore MA, et al. Evaluation of acrivastine + pseudoephedrine in seasonal allergic rhinitis [abstract]. Ann Allergy 1995;55:393.
21. 21. Simons FER, Simons KJ. Peripheral HI-blockade effect of fexofenadine. Ann Allergy Asthma Immunol 1997;79:530-2.
22. 22. Day J, Briscoe M, Welsh A, Smith J, Mason J. Onset of action, efficacy and safety of a single dose of 60 mg and 120 mg fexofenadine HCl for ragweed (RW) allergy using controlled antigen exposure in an environmental exposure unit (EEU). Ann Allergy Asthma Immunol 1997;79:533-40.
23. 23. Tinkleman D, Falliers C, Bronsky E, Kaiser H, Mason J. Efficacy and safety of fexofenadine HCl in fall seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 1996;97:435.
24. 24. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-20.
25. 25. Paolieri F, Riccio AM, Battifora M, et al. MDL16455A and terfenadine (TERF) in vitro activity on human continuous cell lines [abstract]. Allergy 1995;50(Suppl 26):77.
26. 26. Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments. Validation studies in allergic rhinitis. Clin Drug Invest 1996;11:278-88.
27. 27. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
28. 28. Russell T, Stolz M, Eller M, Bhargava V, Weir S. Acute and sub chronic dose tolerance of fexofenadine HCl in healthy male subjects [abstract]. Ann Allergy Asthma Immunol 1996;76:96.